Skip to Content

MYLAN 2035 MYLAN 2035 (Topiramate (Sprinkle) 15 mg)

Pill with imprint MYLAN 2035 MYLAN 2035 is Pink, Capsule-shape and has been identified as Topiramate (Sprinkle) 15 mg. It is supplied by Mylan Pharmaceuticals Inc..

Topiramate is used in the treatment of epilepsy; lennox-gastaut syndrome; migraine prevention; seizure prevention; seizures and belongs to the drug class carbonic anhydrase inhibitor anticonvulsants. There is positive evidence of human fetal risk during pregnancy. Topiramate 15 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for MYLAN 2035 MYLAN 2035

Topiramate (sprinkle) 15 mg MYLAN 2035 MYLAN 2035

Topiramate (Sprinkle)

Imprint
MYLAN 2035 MYLAN 2035
Strength
15 mg
Color
Pink
Shape
Capsule-shape
Availability
Prescription only
Drug Class
Carbonic anhydrase inhibitor anticonvulsants
Pregnancy Category
D - Positive evidence of risk
CSA Schedule
Not a controlled drug
Labeler / Supplier
Mylan Pharmaceuticals Inc.
National Drug Code (NDC)
00378-2035

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.